O4‐08‐06: SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F‐18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β‐AMYLOID PLAQUE‐SPECIFIC ANTIBODY, IN ALZHEIMER’S DISEASE (AD)
The DOI matches its Crossref record.
Abstract
LY3002813 (LY), a humanized IgG1 monoclonal antibody, was engineered to reduce existing amyloid plaque in AD by targeting Aβp3-X—a truncated N-terminally pyro-glutamate modified amyloid beta peptide specifically localized to deposited plaque. In the PDAPP mouse model of cerebral amyloidosis, the murine version of the antibody removed amyloid plaque without increasing microhemorrhage risk (Neuron 2012;76:908-20). We conducted a Phase 1 study in AD patients to assess the safety, PK, and pharmacodynamics (amyloid plaque burden assessed by florbetapir PET) of multiple dose LY (ClinicalTrials.gov Identifier: NCT01837641). Amyloid-positive prodromal to moderate AD patients were administered a single IV dose of LY (0.1 mg/kg IV to 10 mg/kg IV) or placebo during the single ascending dose (SAD) phase, followed by a 12 week follow-up period. The same patients proceeded into the multiple-ascending dose (MAD) phase and were administered up to 4 additional monthly IV doses of LY (0.3 mg/kg IV to 10 mg/kg IV) or placebo, depending on the initial SAD cohort. Adverse events, vital signs, ECGs, clinical laboratories, and neurological exams were assessed throughout the study and for up to 84 days after last dose to characterize safety and tolerability. 37 patients received LY and 12 received placebo in the SAD/MAD cohorts. The 49 subjects had a mean age of 74 yrs (±8yrs) with 57% female and 43% male. 53% had a Clinical Dementia Rating (CDR)=0.5; 43% had CDR=1, and 4% had CDR=2. Subjects had florbetapir PET scans at screening and 7 months after the first dose (233±44 days from screening) for quantitation of change in cerebral amyloid burden. MRI assessments for amyloid related imaging abnormalities were performed at screening, four weeks after the single dose, and at the end of the multiple dose phase. PK and immunogenicity assessments were performed throughout the trial. Safety, pharmacokinetics (PK), and florbetapir PET after multiple dose administration of LY will be presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Self-citationThe amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
“Donanemab was very effective in reducing the florbetapir amyloid PET signal: at 20mg/kg Q4W there was a 68 CL reduction from baseline levels at 24 weeks 82 .”
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Huang, L.-K., Kuan, Y.-C., Lin, H.-W., & Hu, C.-J. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00976-6 · Cited by 252
“It recognizes Aβ (3–42), an aggregated form of Aβ found in amyloid plaques [46].”
Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches
Hussain, R., Zubair, H., Pursell, S., & Shahab, M. (2018) · Brain Sciences · doi:10.3390/brainsci8090177 · Cited by 229
Cao, Y., Yu, F., Lyu, Y., & Lu, X. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1034243 · Cited by 26
Metadata
- Authors
- Irizarry, M. C., Sims, J. R., Lowe, S. L., Nakano, M., Hawdon, A., Willis, B. A., Gonzales, C., Liu, P., Fujimoto, S., Dean, R. A., Konrad, R. J., Shcherbinin, S., Schwarz, A. J., Mintun, M. A., Devous, M. D., DeMattos, R. B., & A.A.C.C. Investigators
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-07
- Volume
- 12
- Issue
- 7S_Part_7
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2535816676
- Cited by
- 25
- References
- 0
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.